Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Miskolc – page 4

90 clinical trials in Miskolc, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.

Miskolc at a glance
90
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

90 trials in Miskolc

Open in trial search

Arteriosclerosis

Not recruiting

A study to evaluate the effect of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease and high levels of lipoprotein(a)

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

Cardiac failure

Not recruiting

A study comparing ziltivekimab to placebo in patients with heart failure with mildly reduced or preserved ejection fraction and inflammation

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Arteriosclerosis

Not recruiting

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Hypertriglyceridaemia

Not recruiting

Long-Term Safety Study of Plozasiran for Adults with High Triglycerides

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Muscle spasticity

Not recruiting

Study on the Safety and Effectiveness of IPN10200 for Treating Upper Limb Spasticity in Adults After Stroke or Brain Injury

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Botulinum Toxin Type A - Haemagglutinin Complex
  • Sponsor:Ipsen Innovation

Arteriosclerosis

Not recruiting

Study on the Effects of Pelacarsen on Heart Disease in Patients with Cardiovascular Conditions

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen
  • Sponsor:Novartis Pharma AG

Hypertriglyceridaemia

Not recruiting

Study to Evaluate Plozasiran for Adults with High Triglycerides

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Dyslipidaemia

Not recruiting

Study of Evolocumab to Prevent Heart Disease Events in High-Risk Patients Without Previous Heart Attack or Stroke

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Evolocumab
  • Sponsor:Amgen Inc.

Dermatitis atopic

Not recruiting

Study on Long-Term Safety and Effectiveness of Abrocitinib for Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis

Registered drug
Countries:HungaryHungary
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Abrocitinib
  • Sponsor:Pfizer Inc.

Arteriosclerosis

Not recruiting

Study on the Effect of Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease Not Adequately Managed by Current Lipid-Lowering Treatments

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Obicetrapib
  • Sponsor:NewAmsterdam Pharma B.V.

Study of Pembrolizumab and Axitinib Combination Versus Sunitinib for Patients with Advanced or Metastatic Kidney Cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Axitinib
  • Sponsor:Merck Sharp & Dohme LLC

Colitis ulcerative

Not recruiting

Study on the Effectiveness and Safety of PB016 and Vedolizumab for Patients with Moderately to Severely Active Ulcerative Colitis

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Vedolizumab
  • Sponsor:Polpharma Biologics S.A.

Other cities in Hungary

The busiest research cities in the country

All 71 cities in Hungary

Clinical research in Miskolc

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on breast cancer treatments, including studies for both triple-negative and ER+/HER2- variants. Research includes evaluation of new therapeutic combinations and prostate cancer treatments.

  • Advanced/Metastatic Breast Cancer
  • Triple-Negative Breast Cancer
  • Metastatic Castration-Resistant Prostate Cancer

Studies emphasize novel treatment approaches and combination therapies for improving patient outcomes.

02 Cardiovascular Studies

Comprehensive research into cardiovascular diseases and preventive treatments, including studies on stroke prevention and atherosclerosis management.

  • Heart Failure Management
  • Stroke Prevention
  • Deep Vein Thrombosis

Trials evaluate new medications for reducing cardiovascular events and improving patient outcomes.

03 Immunology and Inflammation

Investigations into treatments for inflammatory conditions and autoimmune disorders, with particular focus on dermatological and gastrointestinal diseases.

  • Atopic Dermatitis
  • Ulcerative Colitis
  • IgA Nephropathy

Research aims to develop targeted therapies for chronic inflammatory conditions.

04 Pediatric Medicine

Studies focusing on children's health, including respiratory infections, vaccine development, and treatment of childhood diseases.

  • Childhood Leukemia
  • Respiratory Syncytial Virus Prevention
  • Pediatric Ulcerative Colitis

Emphasis on developing safe and effective treatments for young patients.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.